全球抗体热门创造和发现市场 - 分析和预测（2023-2032）

全球抗体命中生成和发现市场规模是由慢性病的增加、抗体工程的进步以及研发投资的增加所推动的。

此外，个人化医疗需求的成长和生物製药产业的扩张也促进了市场的良性循环。

该报告考察了全球抗体命中生成和发现市场，并提供了市场概述，包括按应用、技术、抗体类型、地区和进入市场的公司概况分類的趋势。

目录

执行摘要

调查范围

调查方法

第一章 市场

• 全球市场展望
• 产品定义
• 纳入与排除标准
• 主要发现
• 先决条件和限制
• 世界市场情景
• 产业展望
• 主要趋势
• 专利分析
• 产品基准评效
• COVID-19 对全球抗体命中生成和发现市场的影响
• 对市场规模的影响
• 市场进入障碍与机会
• 业务动态
• 影响分析

第二章 全球抗体创造与发现市场（按技术）

• 机会评估
• 成长占有率矩阵

第三章 全球抗体创造与发现市场（按抗体类型）

• 机会评估
• 成长占有率矩阵

第四章 全球抗体创造与发现市场（依应用）

• 机会评估
• 成长占有率矩阵

第五章 区域

• 北美抗体进入创造和发现市场
• 欧洲抗体进入创造和发现市场
• 亚太地区抗体创造与发现市场
• 拉丁美洲抗体衝击创造与发现市场
• 抗体衝击其他地区的创造和发现市场

第六章市场

• 竞争基准化分析和公司简介
• 竞争形势
  • 关键策略和发展
• 公司简介
  • F. Hoffmann-La Roche Ltd.
  • AbbVie
  • Pfizer
  • AstraZeneca
  • Novartis
  • Eli Lilly
  • WuXi AppTec
  • Charles River Laboratories
  • Syngenta
  • BioLegend
  • Creative Biolabs
  • Eurofins CDMO
  • AbCellera
  • MorphoSys
  • Evelo Biosciences
  • Icos Therapeutics
  • Argenx
  • Kymab
  • Alnylam Pharmaceuticals
  • SAb Biotherapeutics
  • 其他公司

The Global Antibody Hit Generation and Screening Market report offers a detailed and comprehensive analysis of the industry, providing valuable insights into market trends, growth drivers, challenges, and future opportunities. The report covers key segments, competitive landscape, and emerging technologies, offering stakeholders a holistic view of the global market.

The study identifies and analyzes the primary drivers influencing market growth. Factors such as the increasing prevalence of chronic diseases, advancements in antibody engineering, and rising investments in research and development are explored. Additionally, the growing demand for personalized medicine and the expanding biopharmaceutical industry contribute to the positive trajectory of the market.

Market Segmentation:

Segmentation 1: by Application

• Cancer
• Autoimmune diseases
• Infectious diseases

Segmentation 2: by Technologies

• Hit Generation
• Phage display
• Yeast display
• Ribosome display
• B-cell hybridoma technology
• Computational tools
• Screening

Segmentation 3: by Antibody Type

• Humanized Antibody
• Human Antibody
• Chimeric Antibody
• Murine Antibody

Segmentation 4: by Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Rest-of-the-World

Some prominent players established in this market are:

• Creative Biolabs
• F. Hoffmann-La Roche Ltd.
• WuXi AppTec
• Icos Therapeutics

Key Questions Answered:

• What are the major market drivers, challenges and opportunities in the global antibody hit generation and screening market?
• How the antibody hit generation and screening market evolves and what did is its scope in the future?
• How will each segment of the global antibody hit generation and screening market grow during the forecast period?
• How will the industry evolve during the forecast period?
• What are the key developmental strategies implemented by the key players to stand out in this market?

Table of Contents

Executive Summary

Scope of the Study

Research Methodology

1. Market

• 1.1. Global Market Outlook
• 1.2. Product Definition
• 1.3. Inclusion and Exclusion Criteria
• 1.4. Key Findings
• 1.5. Assumptions and Limitations
• 1.6. Global Market Scenario
  • 1.6.1. Realistic Scenario
  • 1.6.2. Optimistic Scenario
  • 1.6.3. Pessimistic Scenario
• 1.7. Industry Outlook
• 1.8. Key Trends
• 1.9. Patent Analysis
  • 1.9.1. Awaited Technological Developments
  • 1.9.2. Patent Filing Trend (by Country/Cluster)
  • 1.9.3. Patent Filing Trend (by Year)
• 1.10. Product Benchmarking
• 1.11. Impact of COVID-19 on Global Antibody Hit Generation and Screening Market
• 1.12. Impact on Market Size
  • 1.12.1. Pre-COVID-19 Phase
  • 1.12.2. During-COVID-19 Phase
  • 1.12.3. Post-COVID-19 Phase
• 1.13. Market Entry Barriers and Opportunities
• 1.14. Business Dynamics
• 1.15. Impact Analysis
  • 1.15.1. Business Drivers
  • 1.15.2. Business Restraints
  • 1.15.3. Business Opportunities

2. Global Antibody Hit Generation and Screening Market (by Technologies)

• 2.1. Opportunity Assessment
• 2.2. Growth Share Matrix
  • 2.2.1. Hit Generation
  • 2.2.2. Phage display
  • 2.2.3. Yeast display
  • 2.2.4. Ribosome display
  • 2.2.5. B-cell hybridoma technology
  • 2.2.6. Computational tools
  • 2.2.7. Screening

3. Global Antibody Hit Generation and Screening Market (by Antibody Type)

• 3.1. Opportunity Assessment
• 3.2. Growth Share Matrix
  • 3.2.1. Humanized Antibody
  • 3.2.2. Human Antibody
  • 3.2.3. Chimeric Antibody
  • 3.2.4. Murine Antibody

4. Global Antibody Hit Generation and Screening Market (by Applications)

• 4.1. Opportunity Assessment
• 4.2. Growth Share Matrix
  • 4.2.1. Cancer
  • 4.2.2. Autoimmune diseases
  • 4.2.3. Infectious diseases

5. Region

• 5.1. North America Antibody Hit Generation and Screening Market
• 5.2. Key Findings and Opportunity Assessment
• 5.3. Regulatory Framework
• 5.4. Market Dynamics
  • 5.4.1. Impact Analysis
• 5.5. Sizing and Forecast Analysis
  • 5.5.1. North America Antibody Hit Generation and Screening Market (by Technologies)
  • 5.5.2. North America Antibody Hit Generation and Screening Market (by Country)
    • 5.5.2.1.1. U.S.
    • 5.5.2.1.2. Canada
• 5.6. Europe Antibody Hit Generation and Screening Market
• 5.7. Key Findings and Opportunity Assessment
• 5.8. Regulatory Framework
• 5.9. Market Dynamics
  • 5.9.1. Impact Analysis
• 5.10. Sizing and Forecast Analysis
  • 5.10.1. Europe Antibody Hit Generation and Screening Market (by Technologies)
  • 5.10.2. Europe Antibody Hit Generation and Screening Market (by Country)
    • 5.10.2.1.1. Germany
    • 5.10.2.1.2. France
    • 5.10.2.1.3. U.K.
    • 5.10.2.1.4. Italy
    • 5.10.2.1.5. Spain
    • 5.10.2.1.6. Rest-of-Europe
• 5.11. Asia-Pacific Antibody Hit Generation and Screening Market
• 5.12. Key Findings and Opportunity Assessment
• 5.13. Regulatory Framework
• 5.14. Market Dynamics
  • 5.14.1. Impact Analysis
• 5.15. Sizing and Forecast Analysis
  • 5.15.1. Asia-Pacific Antibody Hit Generation and Screening Market (by Technologies)
  • 5.15.2. Asia-Pacific Antibody Hit Generation and Screening Market (by Country)
    • 5.15.2.1.1. Japan
    • 5.15.2.1.2. China
    • 5.15.2.1.3. Australia
    • 5.15.2.1.4. India
    • 5.15.2.1.5. South Korea
    • 5.15.2.1.6. Rest-of-Asia-Pacific
• 5.16. Latin America Antibody Hit Generation and Screening Market
• 5.17. Key Findings and Opportunity Assessment
• 5.18. Regulatory Framework
• 5.19. Market Dynamics
  • 5.19.1. Impact Analysis
• 5.20. Sizing and Forecast Analysis
  • 5.20.1. Latin America Antibody Hit Generation and Screening Market (by Technologies)
  • 5.20.2. Latin America Antibody Hit Generation and Screening Market (by Country)
    • 5.20.2.1.1. Brazil
    • 5.20.2.1.2. Mexico
    • 5.20.2.1.3. Rest-of-Latin America
• 5.21. Rest-of-the-World Antibody Hit Generation and Screening Market
• 5.22. Key Findings and Opportunity Assessment
• 5.23. Regulatory Framework
• 5.24. Market Dynamics
  • 5.24.1. Impact Analysis
• 5.25. Sizing and Forecast Analysis
  • 5.25.1. Rest-of-the-World Antibody Hit Generation and Screening Market (by Technologies)

6. Markets

• 6.1. Competitive Benchmarking and Company Profiles
• 6.2. Competitive Landscape
  • 6.2.1. Key Strategies and Developments
    • 6.2.1.1.1. Partnerships, Alliances, and Business Expansion
    • 6.2.1.1.2. Funding Activities
    • 6.2.1.1.3. New Offerings
    • 6.2.1.1.4. Mergers and Acquisitions
    • 6.2.1.1.5. Regulatory and Legal Activities
• 6.3. Company Profiles
  • 6.3.1. F. Hoffmann-La Roche Ltd.
  • 6.3.2. Company Overview
  • 6.3.3. Product Portfolio
  • 6.3.4. Financials
  • 6.3.5. Recent Developments
  • 6.3.6. Analyst Perspective
  • 6.3.7. AbbVie
  • 6.3.8. Pfizer
  • 6.3.9. AstraZeneca
  • 6.3.10. Novartis
  • 6.3.11. Eli Lilly
  • 6.3.12. WuXi AppTec
  • 6.3.13. Charles River Laboratories
  • 6.3.14. Syngenta
  • 6.3.15. BioLegend
  • 6.3.16. Creative Biolabs
  • 6.3.17. Eurofins CDMO
  • 6.3.18. AbCellera
  • 6.3.19. MorphoSys
  • 6.3.20. Evelo Biosciences
  • 6.3.21. Icos Therapeutics
  • 6.3.22. Argenx
  • 6.3.23. Kymab
  • 6.3.24. Alnylam Pharmaceuticals
  • 6.3.25. SAb Biotherapeutics
  • 6.3.26. Other Companies

* Financials are provided for the public companies only